BioPharma conference examines health care issues
Lehigh's BioPharma Business Conference Series, created to provide an interdisciplinary forum where business leaders can exchange insights and learn new strategies, will present Health Care Policy, a Changing Market, and Prospects for Biotech at Rauch Business Center on April 15.
Hosted by the Martindale Center in the College of Business and Economics, this conference will run from 1:30 p.m. to 8:30 p.m. and address key challenges of doing business in the rapidly changing marketplace.
The 2004 conference will focus on specific issues related to domestic and international health care policy and how they affect future U.S. markets for pharmaceutical and biotech products and innovation in medical science and technology.
Robert J. Rubin, clinical professor of medicine at Georgetown University and former president of the Lewin Group, is the first keynote speaker. He will address the state of the domestic marketplace. Jeffrey Sturchio, vice president - External Affairs, Human Health - Europe, Middle East, and Africa, for Merck and Co., Inc., will deliver the second keynote presentation on the international dimensions of current biopharmaceutical market issues.
The cost of drugs as a percentage of total health care spending has doubled in the last two decades. In order to reduce the cost of prescription drug plans, government and private health care insurers are beginning to implement programs that will control reimbursement levels, says Arthur King, professor of economics and director of the Martindale Center’s BioPharma Business Conference Series.
The conference will bring together industry leaders and health care policy experts to focus on market and policy changes in the United States and abroad. Panelists include Barry R. Edwards,CEO, Impax Laboratories, Inc., William A. Fletcher, president and CEO, Teva North America, Elaine V. Jones, general partner, EuclidSR Partners, and Daniel R. Omstead, president and CEO, Hambrecht & Quist Capital Management, Inc.
They will present their perspectives on biotech investment prospects and the effects of new drug reimbursement polices on strategic company positioning. The program design will engage program participants in dialog about their own viewpoints and concerns as well.
For more information or to register for the conference, please click here.
--Kim Plyler
Hosted by the Martindale Center in the College of Business and Economics, this conference will run from 1:30 p.m. to 8:30 p.m. and address key challenges of doing business in the rapidly changing marketplace.
The 2004 conference will focus on specific issues related to domestic and international health care policy and how they affect future U.S. markets for pharmaceutical and biotech products and innovation in medical science and technology.
Robert J. Rubin, clinical professor of medicine at Georgetown University and former president of the Lewin Group, is the first keynote speaker. He will address the state of the domestic marketplace. Jeffrey Sturchio, vice president - External Affairs, Human Health - Europe, Middle East, and Africa, for Merck and Co., Inc., will deliver the second keynote presentation on the international dimensions of current biopharmaceutical market issues.
The cost of drugs as a percentage of total health care spending has doubled in the last two decades. In order to reduce the cost of prescription drug plans, government and private health care insurers are beginning to implement programs that will control reimbursement levels, says Arthur King, professor of economics and director of the Martindale Center’s BioPharma Business Conference Series.
The conference will bring together industry leaders and health care policy experts to focus on market and policy changes in the United States and abroad. Panelists include Barry R. Edwards,CEO, Impax Laboratories, Inc., William A. Fletcher, president and CEO, Teva North America, Elaine V. Jones, general partner, EuclidSR Partners, and Daniel R. Omstead, president and CEO, Hambrecht & Quist Capital Management, Inc.
They will present their perspectives on biotech investment prospects and the effects of new drug reimbursement polices on strategic company positioning. The program design will engage program participants in dialog about their own viewpoints and concerns as well.
For more information or to register for the conference, please click here.
--Kim Plyler
Posted on:
Monday, March 29, 2004
Share This Story:
